BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Guidance

What This Product Solves

BFH772 (CAS 890128-81-1) is engineered as a potent small-molecule VEGFR2 inhibitor for research requiring specific suppression of VEGFR2-mediated angiogenesis. Its selectivity profile, with an IC50 of 3 nM for VEGFR2 and markedly reduced potency toward related kinases, allows researchers to interrogate VEGFR2 signaling with minimal off-target effects. This makes BFH772 an effective tool for dissecting the contributions of VEGFR2 pathways in tumor angiogenesis and for evaluating anti-angiogenic strategies in preclinical models. In contrast, it is not appropriate for experiments that demand water-soluble reagents or broad kinase inhibition (product_spec).

For additional technical context, see "BFH772 (VEGFR2 inhibitor): Technical Guidance for Angiogenesis Research" for discussion of solubility and selectivity in tumor models, and "BFH772 (VEGFR2 inhibitor): Protocols, Use, and QC Guidance" for in-depth protocol recommendations.

Protocol Parameters

• assay: VEGFR2 kinase inhibition assay | value_with_unit: IC50 = 3 nM | applicability: Quantitative measurement of VEGFR2 inhibition potency | rationale: Enables precise titration and benchmarking against other VEGFR2 pathway inhibitors | source_type: product_spec (product_spec)
• assay: Solubility testing in DMSO and ethanol | value_with_unit: ≥53.4 mg/mL (DMSO), ≥15.33 mg/mL (ethanol) | applicability: Preparation of concentrated stock solutions for in vitro and in vivo applications | rationale: Ensures compound is fully dissolved for accurate dosing and minimal vehicle effects | source_type: product_spec
• assay: Storage stability | value_with_unit: -20°C (solid form), avoid long-term storage of solutions | applicability: Maintenance of compound potency and prevention of degradation during storage | rationale: Preserves chemical integrity and reproducibility across experiments | source_type: product_spec
• assay: Selectivity assessment against related kinases | value_with_unit: ~500-fold lower potency for FLK-1, FLT-1, FLT-4; ~40-fold lower for B-RAF, RET, TIE-2 | applicability: Choice of compound for studies requiring high VEGFR2 specificity | rationale: Minimizes confounding by off-target kinase inhibition | source_type: product_spec
• assay: Vehicle compatibility test | value_with_unit: DMSO and ethanol only; insoluble in water | applicability: Ensures compatibility with assay system and avoids precipitation | rationale: Prevents loss of activity or inconsistent bioavailability | source_type: workflow_recommendation

Workflow Setup and QC Checklist

• Prepare BFH772 stock solutions in DMSO or ethanol according to solubility data (≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol). Avoid water as a solvent due to insolubility (product_spec).
• Aliquot stock solutions to minimize freeze-thaw cycles. Store solid compound at -20°C; avoid long-term storage of solutions to prevent degradation.
• Verify batch purity (≥96%) and consult the provided certificate of analysis and safety data sheet for each lot.
• Confirm vehicle compatibility with your assay system prior to use, ensuring that final DMSO or ethanol concentrations do not exceed cytotoxic thresholds for your cell type or model.
• Include appropriate positive and negative controls (e.g., known VEGFR2 inhibitors, vehicle-only) to benchmark assay sensitivity and specificity.
• Document each step, including preparation, handling, and disposal, in accordance with institutional safety protocols and APExBIO recommendations.

Common Failure Modes and Fixes

• Precipitation in aqueous media: As BFH772 is insoluble in water, improper dilution can cause precipitation and loss of activity. Fix: Prepare and dilute stocks only in DMSO or ethanol, and add to assay media with thorough mixing. Keep final organic solvent concentration below cytotoxic thresholds.
• Loss of potency due to improper storage: Extended storage of BFH772 solutions at room temperature or repeated freeze-thaw cycles can degrade compound integrity. Fix: Store solid at -20°C and prepare fresh solutions as needed (product_spec).
• Off-target effects at excessive dosing: Although BFH772 is highly selective, supra-physiological concentrations may lead to partial inhibition of related kinases. Fix: Use concentrations within the nanomolar range as guided by IC50 data and titrate carefully according to experimental needs.
• Inconsistent assay results: Variability in compound handling, vehicle concentration, or batch purity can affect data reproducibility. Fix: Standardize all preparation steps and use quality-controlled materials as provided by APExBIO.

Scope and Limitations

BFH772 is optimized for research focused on VEGFR2-mediated angiogenesis, particularly in tumor model systems. Its selectivity profile limits its use to studies where off-target kinase inhibition is undesirable. The compound's insolubility in water restricts its use in workflows or assays that require aqueous solutions. Additionally, BFH772 is not designed for studies seeking to broadly suppress multiple angiogenic kinases. Researchers should consult existing technical guidance (e.g., BFH772 (VEGFR2 inhibitor): Technical Use and Protocol Parameters) for further application-specific recommendations.

Conclusion

BFH772 (VEGFR2 inhibitor) offers a highly selective, potent approach for dissecting VEGFR2-driven angiogenesis, especially within tumor biology research. By adhering to precise solubility, storage, and assay parameters detailed above, researchers can maximize data reliability and minimize confounding variables. For technical details, certificates, and product documentation, consult the APExBIO BFH772 (VEGFR2 inhibitor) product page.